Global Human Recombinant Insulin Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver.Recombinant human insulin has a significant advantage over insulin from other animal sources. Patients can better absorb human insulin.It is also easier to manage allergies related to insulin intake.
LPI (LP Information)' newest research report, the “Human Recombinant Insulin Industry Forecast” looks at past sales and reviews total world Human Recombinant Insulin sales in 2022, providing a comprehensive analysis by region and market sector of projected Human Recombinant Insulin sales for 2023 through 2029. With Human Recombinant Insulin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Recombinant Insulin industry.
This Insight Report provides a comprehensive analysis of the global Human Recombinant Insulin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Recombinant Insulin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Human Recombinant Insulin market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Recombinant Insulin and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Recombinant Insulin.
The global Human Recombinant Insulin market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Human Recombinant Insulin is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Human Recombinant Insulin is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Human Recombinant Insulin is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Human Recombinant Insulin players cover Novo Nordisk, Eli Lilly and Company, Sanofi, Julphar Gulf Pharmaceutical Industries, Bioton, Gan & Lee Pharmaceuticals, Zhuhai United Laboratories, Biocon and Wanbang Biopharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Recombinant Insulin market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Human Recombinant Insulin market?
What factors are driving Human Recombinant Insulin market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Human Recombinant Insulin market opportunities vary by end market size?
How does Human Recombinant Insulin break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver.Recombinant human insulin has a significant advantage over insulin from other animal sources. Patients can better absorb human insulin.It is also easier to manage allergies related to insulin intake.
LPI (LP Information)' newest research report, the “Human Recombinant Insulin Industry Forecast” looks at past sales and reviews total world Human Recombinant Insulin sales in 2022, providing a comprehensive analysis by region and market sector of projected Human Recombinant Insulin sales for 2023 through 2029. With Human Recombinant Insulin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Recombinant Insulin industry.
This Insight Report provides a comprehensive analysis of the global Human Recombinant Insulin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Recombinant Insulin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Human Recombinant Insulin market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Recombinant Insulin and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Recombinant Insulin.
The global Human Recombinant Insulin market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Human Recombinant Insulin is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Human Recombinant Insulin is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Human Recombinant Insulin is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Human Recombinant Insulin players cover Novo Nordisk, Eli Lilly and Company, Sanofi, Julphar Gulf Pharmaceutical Industries, Bioton, Gan & Lee Pharmaceuticals, Zhuhai United Laboratories, Biocon and Wanbang Biopharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Recombinant Insulin market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Rapid-Acting Human Insulin
- Regular (Short Acting) Insulin
- NPH (Intermediate Acting) Insulin
- Long-Acting Human Insulin
- Premixed Human Insulins Insulin
- Hospital
- Retail Pharmacy
- Online Pharmacies
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novo Nordisk
- Eli Lilly and Company
- Sanofi
- Julphar Gulf Pharmaceutical Industries
- Bioton
- Gan & Lee Pharmaceuticals
- Zhuhai United Laboratories
- Biocon
- Wanbang Biopharmaceuticals
- Dongbao Enterprise Group
- PeproTech
What is the 10-year outlook for the global Human Recombinant Insulin market?
What factors are driving Human Recombinant Insulin market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Human Recombinant Insulin market opportunities vary by end market size?
How does Human Recombinant Insulin break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Human Recombinant Insulin Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Human Recombinant Insulin by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Human Recombinant Insulin by Country/Region, 2018, 2022 & 2029
2.2 Human Recombinant Insulin Segment by Type
2.2.1 Rapid-Acting Human Insulin
2.2.2 Regular (Short Acting) Insulin
2.2.3 NPH (Intermediate Acting) Insulin
2.2.4 Long-Acting Human Insulin
2.2.5 Premixed Human Insulins Insulin
2.3 Human Recombinant Insulin Sales by Type
2.3.1 Global Human Recombinant Insulin Sales Market Share by Type (2018-2023)
2.3.2 Global Human Recombinant Insulin Revenue and Market Share by Type (2018-2023)
2.3.3 Global Human Recombinant Insulin Sale Price by Type (2018-2023)
2.4 Human Recombinant Insulin Segment by Application
2.4.1 Hospital
2.4.2 Retail Pharmacy
2.4.3 Online Pharmacies
2.4.4 Other
2.5 Human Recombinant Insulin Sales by Application
2.5.1 Global Human Recombinant Insulin Sale Market Share by Application (2018-2023)
2.5.2 Global Human Recombinant Insulin Revenue and Market Share by Application (2018-2023)
2.5.3 Global Human Recombinant Insulin Sale Price by Application (2018-2023)
3 GLOBAL HUMAN RECOMBINANT INSULIN BY COMPANY
3.1 Global Human Recombinant Insulin Breakdown Data by Company
3.1.1 Global Human Recombinant Insulin Annual Sales by Company (2018-2023)
3.1.2 Global Human Recombinant Insulin Sales Market Share by Company (2018-2023)
3.2 Global Human Recombinant Insulin Annual Revenue by Company (2018-2023)
3.2.1 Global Human Recombinant Insulin Revenue by Company (2018-2023)
3.2.2 Global Human Recombinant Insulin Revenue Market Share by Company (2018-2023)
3.3 Global Human Recombinant Insulin Sale Price by Company
3.4 Key Manufacturers Human Recombinant Insulin Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Human Recombinant Insulin Product Location Distribution
3.4.2 Players Human Recombinant Insulin Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR HUMAN RECOMBINANT INSULIN BY GEOGRAPHIC REGION
4.1 World Historic Human Recombinant Insulin Market Size by Geographic Region (2018-2023)
4.1.1 Global Human Recombinant Insulin Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Human Recombinant Insulin Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Human Recombinant Insulin Market Size by Country/Region (2018-2023)
4.2.1 Global Human Recombinant Insulin Annual Sales by Country/Region (2018-2023)
4.2.2 Global Human Recombinant Insulin Annual Revenue by Country/Region (2018-2023)
4.3 Americas Human Recombinant Insulin Sales Growth
4.4 APAC Human Recombinant Insulin Sales Growth
4.5 Europe Human Recombinant Insulin Sales Growth
4.6 Middle East & Africa Human Recombinant Insulin Sales Growth
5 AMERICAS
5.1 Americas Human Recombinant Insulin Sales by Country
5.1.1 Americas Human Recombinant Insulin Sales by Country (2018-2023)
5.1.2 Americas Human Recombinant Insulin Revenue by Country (2018-2023)
5.2 Americas Human Recombinant Insulin Sales by Type
5.3 Americas Human Recombinant Insulin Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Recombinant Insulin Sales by Region
6.1.1 APAC Human Recombinant Insulin Sales by Region (2018-2023)
6.1.2 APAC Human Recombinant Insulin Revenue by Region (2018-2023)
6.2 APAC Human Recombinant Insulin Sales by Type
6.3 APAC Human Recombinant Insulin Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Human Recombinant Insulin by Country
7.1.1 Europe Human Recombinant Insulin Sales by Country (2018-2023)
7.1.2 Europe Human Recombinant Insulin Revenue by Country (2018-2023)
7.2 Europe Human Recombinant Insulin Sales by Type
7.3 Europe Human Recombinant Insulin Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Human Recombinant Insulin by Country
8.1.1 Middle East & Africa Human Recombinant Insulin Sales by Country (2018-2023)
8.1.2 Middle East & Africa Human Recombinant Insulin Revenue by Country (2018-2023)
8.2 Middle East & Africa Human Recombinant Insulin Sales by Type
8.3 Middle East & Africa Human Recombinant Insulin Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Human Recombinant Insulin
10.3 Manufacturing Process Analysis of Human Recombinant Insulin
10.4 Industry Chain Structure of Human Recombinant Insulin
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Human Recombinant Insulin Distributors
11.3 Human Recombinant Insulin Customer
12 WORLD FORECAST REVIEW FOR HUMAN RECOMBINANT INSULIN BY GEOGRAPHIC REGION
12.1 Global Human Recombinant Insulin Market Size Forecast by Region
12.1.1 Global Human Recombinant Insulin Forecast by Region (2024-2029)
12.1.2 Global Human Recombinant Insulin Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Human Recombinant Insulin Forecast by Type
12.7 Global Human Recombinant Insulin Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Novo Nordisk
13.1.1 Novo Nordisk Company Information
13.1.2 Novo Nordisk Human Recombinant Insulin Product Portfolios and Specifications
13.1.3 Novo Nordisk Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Novo Nordisk Main Business Overview
13.1.5 Novo Nordisk Latest Developments
13.2 Eli Lilly and Company
13.2.1 Eli Lilly and Company Company Information
13.2.2 Eli Lilly and Company Human Recombinant Insulin Product Portfolios and Specifications
13.2.3 Eli Lilly and Company Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Eli Lilly and Company Main Business Overview
13.2.5 Eli Lilly and Company Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Human Recombinant Insulin Product Portfolios and Specifications
13.3.3 Sanofi Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Julphar Gulf Pharmaceutical Industries
13.4.1 Julphar Gulf Pharmaceutical Industries Company Information
13.4.2 Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Product Portfolios and Specifications
13.4.3 Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Julphar Gulf Pharmaceutical Industries Main Business Overview
13.4.5 Julphar Gulf Pharmaceutical Industries Latest Developments
13.5 Bioton
13.5.1 Bioton Company Information
13.5.2 Bioton Human Recombinant Insulin Product Portfolios and Specifications
13.5.3 Bioton Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Bioton Main Business Overview
13.5.5 Bioton Latest Developments
13.6 Gan & Lee Pharmaceuticals
13.6.1 Gan & Lee Pharmaceuticals Company Information
13.6.2 Gan & Lee Pharmaceuticals Human Recombinant Insulin Product Portfolios and Specifications
13.6.3 Gan & Lee Pharmaceuticals Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Gan & Lee Pharmaceuticals Main Business Overview
13.6.5 Gan & Lee Pharmaceuticals Latest Developments
13.7 Zhuhai United Laboratories
13.7.1 Zhuhai United Laboratories Company Information
13.7.2 Zhuhai United Laboratories Human Recombinant Insulin Product Portfolios and Specifications
13.7.3 Zhuhai United Laboratories Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Zhuhai United Laboratories Main Business Overview
13.7.5 Zhuhai United Laboratories Latest Developments
13.8 Biocon
13.8.1 Biocon Company Information
13.8.2 Biocon Human Recombinant Insulin Product Portfolios and Specifications
13.8.3 Biocon Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Biocon Main Business Overview
13.8.5 Biocon Latest Developments
13.9 Wanbang Biopharmaceuticals
13.9.1 Wanbang Biopharmaceuticals Company Information
13.9.2 Wanbang Biopharmaceuticals Human Recombinant Insulin Product Portfolios and Specifications
13.9.3 Wanbang Biopharmaceuticals Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Wanbang Biopharmaceuticals Main Business Overview
13.9.5 Wanbang Biopharmaceuticals Latest Developments
13.10 Dongbao Enterprise Group
13.10.1 Dongbao Enterprise Group Company Information
13.10.2 Dongbao Enterprise Group Human Recombinant Insulin Product Portfolios and Specifications
13.10.3 Dongbao Enterprise Group Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Dongbao Enterprise Group Main Business Overview
13.10.5 Dongbao Enterprise Group Latest Developments
13.11 PeproTech
13.11.1 PeproTech Company Information
13.11.2 PeproTech Human Recombinant Insulin Product Portfolios and Specifications
13.11.3 PeproTech Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 PeproTech Main Business Overview
13.11.5 PeproTech Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Human Recombinant Insulin Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Human Recombinant Insulin by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Human Recombinant Insulin by Country/Region, 2018, 2022 & 2029
2.2 Human Recombinant Insulin Segment by Type
2.2.1 Rapid-Acting Human Insulin
2.2.2 Regular (Short Acting) Insulin
2.2.3 NPH (Intermediate Acting) Insulin
2.2.4 Long-Acting Human Insulin
2.2.5 Premixed Human Insulins Insulin
2.3 Human Recombinant Insulin Sales by Type
2.3.1 Global Human Recombinant Insulin Sales Market Share by Type (2018-2023)
2.3.2 Global Human Recombinant Insulin Revenue and Market Share by Type (2018-2023)
2.3.3 Global Human Recombinant Insulin Sale Price by Type (2018-2023)
2.4 Human Recombinant Insulin Segment by Application
2.4.1 Hospital
2.4.2 Retail Pharmacy
2.4.3 Online Pharmacies
2.4.4 Other
2.5 Human Recombinant Insulin Sales by Application
2.5.1 Global Human Recombinant Insulin Sale Market Share by Application (2018-2023)
2.5.2 Global Human Recombinant Insulin Revenue and Market Share by Application (2018-2023)
2.5.3 Global Human Recombinant Insulin Sale Price by Application (2018-2023)
3 GLOBAL HUMAN RECOMBINANT INSULIN BY COMPANY
3.1 Global Human Recombinant Insulin Breakdown Data by Company
3.1.1 Global Human Recombinant Insulin Annual Sales by Company (2018-2023)
3.1.2 Global Human Recombinant Insulin Sales Market Share by Company (2018-2023)
3.2 Global Human Recombinant Insulin Annual Revenue by Company (2018-2023)
3.2.1 Global Human Recombinant Insulin Revenue by Company (2018-2023)
3.2.2 Global Human Recombinant Insulin Revenue Market Share by Company (2018-2023)
3.3 Global Human Recombinant Insulin Sale Price by Company
3.4 Key Manufacturers Human Recombinant Insulin Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Human Recombinant Insulin Product Location Distribution
3.4.2 Players Human Recombinant Insulin Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR HUMAN RECOMBINANT INSULIN BY GEOGRAPHIC REGION
4.1 World Historic Human Recombinant Insulin Market Size by Geographic Region (2018-2023)
4.1.1 Global Human Recombinant Insulin Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Human Recombinant Insulin Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Human Recombinant Insulin Market Size by Country/Region (2018-2023)
4.2.1 Global Human Recombinant Insulin Annual Sales by Country/Region (2018-2023)
4.2.2 Global Human Recombinant Insulin Annual Revenue by Country/Region (2018-2023)
4.3 Americas Human Recombinant Insulin Sales Growth
4.4 APAC Human Recombinant Insulin Sales Growth
4.5 Europe Human Recombinant Insulin Sales Growth
4.6 Middle East & Africa Human Recombinant Insulin Sales Growth
5 AMERICAS
5.1 Americas Human Recombinant Insulin Sales by Country
5.1.1 Americas Human Recombinant Insulin Sales by Country (2018-2023)
5.1.2 Americas Human Recombinant Insulin Revenue by Country (2018-2023)
5.2 Americas Human Recombinant Insulin Sales by Type
5.3 Americas Human Recombinant Insulin Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Recombinant Insulin Sales by Region
6.1.1 APAC Human Recombinant Insulin Sales by Region (2018-2023)
6.1.2 APAC Human Recombinant Insulin Revenue by Region (2018-2023)
6.2 APAC Human Recombinant Insulin Sales by Type
6.3 APAC Human Recombinant Insulin Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Human Recombinant Insulin by Country
7.1.1 Europe Human Recombinant Insulin Sales by Country (2018-2023)
7.1.2 Europe Human Recombinant Insulin Revenue by Country (2018-2023)
7.2 Europe Human Recombinant Insulin Sales by Type
7.3 Europe Human Recombinant Insulin Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Human Recombinant Insulin by Country
8.1.1 Middle East & Africa Human Recombinant Insulin Sales by Country (2018-2023)
8.1.2 Middle East & Africa Human Recombinant Insulin Revenue by Country (2018-2023)
8.2 Middle East & Africa Human Recombinant Insulin Sales by Type
8.3 Middle East & Africa Human Recombinant Insulin Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Human Recombinant Insulin
10.3 Manufacturing Process Analysis of Human Recombinant Insulin
10.4 Industry Chain Structure of Human Recombinant Insulin
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Human Recombinant Insulin Distributors
11.3 Human Recombinant Insulin Customer
12 WORLD FORECAST REVIEW FOR HUMAN RECOMBINANT INSULIN BY GEOGRAPHIC REGION
12.1 Global Human Recombinant Insulin Market Size Forecast by Region
12.1.1 Global Human Recombinant Insulin Forecast by Region (2024-2029)
12.1.2 Global Human Recombinant Insulin Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Human Recombinant Insulin Forecast by Type
12.7 Global Human Recombinant Insulin Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Novo Nordisk
13.1.1 Novo Nordisk Company Information
13.1.2 Novo Nordisk Human Recombinant Insulin Product Portfolios and Specifications
13.1.3 Novo Nordisk Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Novo Nordisk Main Business Overview
13.1.5 Novo Nordisk Latest Developments
13.2 Eli Lilly and Company
13.2.1 Eli Lilly and Company Company Information
13.2.2 Eli Lilly and Company Human Recombinant Insulin Product Portfolios and Specifications
13.2.3 Eli Lilly and Company Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Eli Lilly and Company Main Business Overview
13.2.5 Eli Lilly and Company Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Human Recombinant Insulin Product Portfolios and Specifications
13.3.3 Sanofi Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Julphar Gulf Pharmaceutical Industries
13.4.1 Julphar Gulf Pharmaceutical Industries Company Information
13.4.2 Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Product Portfolios and Specifications
13.4.3 Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Julphar Gulf Pharmaceutical Industries Main Business Overview
13.4.5 Julphar Gulf Pharmaceutical Industries Latest Developments
13.5 Bioton
13.5.1 Bioton Company Information
13.5.2 Bioton Human Recombinant Insulin Product Portfolios and Specifications
13.5.3 Bioton Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Bioton Main Business Overview
13.5.5 Bioton Latest Developments
13.6 Gan & Lee Pharmaceuticals
13.6.1 Gan & Lee Pharmaceuticals Company Information
13.6.2 Gan & Lee Pharmaceuticals Human Recombinant Insulin Product Portfolios and Specifications
13.6.3 Gan & Lee Pharmaceuticals Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Gan & Lee Pharmaceuticals Main Business Overview
13.6.5 Gan & Lee Pharmaceuticals Latest Developments
13.7 Zhuhai United Laboratories
13.7.1 Zhuhai United Laboratories Company Information
13.7.2 Zhuhai United Laboratories Human Recombinant Insulin Product Portfolios and Specifications
13.7.3 Zhuhai United Laboratories Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Zhuhai United Laboratories Main Business Overview
13.7.5 Zhuhai United Laboratories Latest Developments
13.8 Biocon
13.8.1 Biocon Company Information
13.8.2 Biocon Human Recombinant Insulin Product Portfolios and Specifications
13.8.3 Biocon Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Biocon Main Business Overview
13.8.5 Biocon Latest Developments
13.9 Wanbang Biopharmaceuticals
13.9.1 Wanbang Biopharmaceuticals Company Information
13.9.2 Wanbang Biopharmaceuticals Human Recombinant Insulin Product Portfolios and Specifications
13.9.3 Wanbang Biopharmaceuticals Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Wanbang Biopharmaceuticals Main Business Overview
13.9.5 Wanbang Biopharmaceuticals Latest Developments
13.10 Dongbao Enterprise Group
13.10.1 Dongbao Enterprise Group Company Information
13.10.2 Dongbao Enterprise Group Human Recombinant Insulin Product Portfolios and Specifications
13.10.3 Dongbao Enterprise Group Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Dongbao Enterprise Group Main Business Overview
13.10.5 Dongbao Enterprise Group Latest Developments
13.11 PeproTech
13.11.1 PeproTech Company Information
13.11.2 PeproTech Human Recombinant Insulin Product Portfolios and Specifications
13.11.3 PeproTech Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 PeproTech Main Business Overview
13.11.5 PeproTech Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Human Recombinant Insulin Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Human Recombinant Insulin Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Rapid-Acting Human Insulin
Table 4. Major Players of Regular (Short Acting) Insulin
Table 5. Major Players of NPH (Intermediate Acting) Insulin
Table 6. Major Players of Long-Acting Human Insulin
Table 7. Major Players of Premixed Human Insulins Insulin
Table 8. Global Human Recombinant Insulin Sales by Type (2018-2023) & (K Litre)
Table 9. Global Human Recombinant Insulin Sales Market Share by Type (2018-2023)
Table 10. Global Human Recombinant Insulin Revenue by Type (2018-2023) & ($ million)
Table 11. Global Human Recombinant Insulin Revenue Market Share by Type (2018-2023)
Table 12. Global Human Recombinant Insulin Sale Price by Type (2018-2023) & (USD/Litre)
Table 13. Global Human Recombinant Insulin Sales by Application (2018-2023) & (K Litre)
Table 14. Global Human Recombinant Insulin Sales Market Share by Application (2018-2023)
Table 15. Global Human Recombinant Insulin Revenue by Application (2018-2023)
Table 16. Global Human Recombinant Insulin Revenue Market Share by Application (2018-2023)
Table 17. Global Human Recombinant Insulin Sale Price by Application (2018-2023) & (USD/Litre)
Table 18. Global Human Recombinant Insulin Sales by Company (2018-2023) & (K Litre)
Table 19. Global Human Recombinant Insulin Sales Market Share by Company (2018-2023)
Table 20. Global Human Recombinant Insulin Revenue by Company (2018-2023) ($ Millions)
Table 21. Global Human Recombinant Insulin Revenue Market Share by Company (2018-2023)
Table 22. Global Human Recombinant Insulin Sale Price by Company (2018-2023) & (USD/Litre)
Table 23. Key Manufacturers Human Recombinant Insulin Producing Area Distribution and Sales Area
Table 24. Players Human Recombinant Insulin Products Offered
Table 25. Human Recombinant Insulin Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Human Recombinant Insulin Sales by Geographic Region (2018-2023) & (K Litre)
Table 29. Global Human Recombinant Insulin Sales Market Share Geographic Region (2018-2023)
Table 30. Global Human Recombinant Insulin Revenue by Geographic Region (2018-2023) & ($ millions)
Table 31. Global Human Recombinant Insulin Revenue Market Share by Geographic Region (2018-2023)
Table 32. Global Human Recombinant Insulin Sales by Country/Region (2018-2023) & (K Litre)
Table 33. Global Human Recombinant Insulin Sales Market Share by Country/Region (2018-2023)
Table 34. Global Human Recombinant Insulin Revenue by Country/Region (2018-2023) & ($ millions)
Table 35. Global Human Recombinant Insulin Revenue Market Share by Country/Region (2018-2023)
Table 36. Americas Human Recombinant Insulin Sales by Country (2018-2023) & (K Litre)
Table 37. Americas Human Recombinant Insulin Sales Market Share by Country (2018-2023)
Table 38. Americas Human Recombinant Insulin Revenue by Country (2018-2023) & ($ Millions)
Table 39. Americas Human Recombinant Insulin Revenue Market Share by Country (2018-2023)
Table 40. Americas Human Recombinant Insulin Sales by Type (2018-2023) & (K Litre)
Table 41. Americas Human Recombinant Insulin Sales by Application (2018-2023) & (K Litre)
Table 42. APAC Human Recombinant Insulin Sales by Region (2018-2023) & (K Litre)
Table 43. APAC Human Recombinant Insulin Sales Market Share by Region (2018-2023)
Table 44. APAC Human Recombinant Insulin Revenue by Region (2018-2023) & ($ Millions)
Table 45. APAC Human Recombinant Insulin Revenue Market Share by Region (2018-2023)
Table 46. APAC Human Recombinant Insulin Sales by Type (2018-2023) & (K Litre)
Table 47. APAC Human Recombinant Insulin Sales by Application (2018-2023) & (K Litre)
Table 48. Europe Human Recombinant Insulin Sales by Country (2018-2023) & (K Litre)
Table 49. Europe Human Recombinant Insulin Sales Market Share by Country (2018-2023)
Table 50. Europe Human Recombinant Insulin Revenue by Country (2018-2023) & ($ Millions)
Table 51. Europe Human Recombinant Insulin Revenue Market Share by Country (2018-2023)
Table 52. Europe Human Recombinant Insulin Sales by Type (2018-2023) & (K Litre)
Table 53. Europe Human Recombinant Insulin Sales by Application (2018-2023) & (K Litre)
Table 54. Middle East & Africa Human Recombinant Insulin Sales by Country (2018-2023) & (K Litre)
Table 55. Middle East & Africa Human Recombinant Insulin Sales Market Share by Country (2018-2023)
Table 56. Middle East & Africa Human Recombinant Insulin Revenue by Country (2018-2023) & ($ Millions)
Table 57. Middle East & Africa Human Recombinant Insulin Revenue Market Share by Country (2018-2023)
Table 58. Middle East & Africa Human Recombinant Insulin Sales by Type (2018-2023) & (K Litre)
Table 59. Middle East & Africa Human Recombinant Insulin Sales by Application (2018-2023) & (K Litre)
Table 60. Key Market Drivers & Growth Opportunities of Human Recombinant Insulin
Table 61. Key Market Challenges & Risks of Human Recombinant Insulin
Table 62. Key Industry Trends of Human Recombinant Insulin
Table 63. Human Recombinant Insulin Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Human Recombinant Insulin Distributors List
Table 66. Human Recombinant Insulin Customer List
Table 67. Global Human Recombinant Insulin Sales Forecast by Region (2024-2029) & (K Litre)
Table 68. Global Human Recombinant Insulin Revenue Forecast by Region (2024-2029) & ($ millions)
Table 69. Americas Human Recombinant Insulin Sales Forecast by Country (2024-2029) & (K Litre)
Table 70. Americas Human Recombinant Insulin Revenue Forecast by Country (2024-2029) & ($ millions)
Table 71. APAC Human Recombinant Insulin Sales Forecast by Region (2024-2029) & (K Litre)
Table 72. APAC Human Recombinant Insulin Revenue Forecast by Region (2024-2029) & ($ millions)
Table 73. Europe Human Recombinant Insulin Sales Forecast by Country (2024-2029) & (K Litre)
Table 74. Europe Human Recombinant Insulin Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Middle East & Africa Human Recombinant Insulin Sales Forecast by Country (2024-2029) & (K Litre)
Table 76. Middle East & Africa Human Recombinant Insulin Revenue Forecast by Country (2024-2029) & ($ millions)
Table 77. Global Human Recombinant Insulin Sales Forecast by Type (2024-2029) & (K Litre)
Table 78. Global Human Recombinant Insulin Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 79. Global Human Recombinant Insulin Sales Forecast by Application (2024-2029) & (K Litre)
Table 80. Global Human Recombinant Insulin Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 81. Novo Nordisk Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 82. Novo Nordisk Human Recombinant Insulin Product Portfolios and Specifications
Table 83. Novo Nordisk Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 84. Novo Nordisk Main Business
Table 85. Novo Nordisk Latest Developments
Table 86. Eli Lilly and Company Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 87. Eli Lilly and Company Human Recombinant Insulin Product Portfolios and Specifications
Table 88. Eli Lilly and Company Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 89. Eli Lilly and Company Main Business
Table 90. Eli Lilly and Company Latest Developments
Table 91. Sanofi Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 92. Sanofi Human Recombinant Insulin Product Portfolios and Specifications
Table 93. Sanofi Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 94. Sanofi Main Business
Table 95. Sanofi Latest Developments
Table 96. Julphar Gulf Pharmaceutical Industries Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 97. Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Product Portfolios and Specifications
Table 98. Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 99. Julphar Gulf Pharmaceutical Industries Main Business
Table 100. Julphar Gulf Pharmaceutical Industries Latest Developments
Table 101. Bioton Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 102. Bioton Human Recombinant Insulin Product Portfolios and Specifications
Table 103. Bioton Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 104. Bioton Main Business
Table 105. Bioton Latest Developments
Table 106. Gan & Lee Pharmaceuticals Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 107. Gan & Lee Pharmaceuticals Human Recombinant Insulin Product Portfolios and Specifications
Table 108. Gan & Lee Pharmaceuticals Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 109. Gan & Lee Pharmaceuticals Main Business
Table 110. Gan & Lee Pharmaceuticals Latest Developments
Table 111. Zhuhai United Laboratories Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 112. Zhuhai United Laboratories Human Recombinant Insulin Product Portfolios and Specifications
Table 113. Zhuhai United Laboratories Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 114. Zhuhai United Laboratories Main Business
Table 115. Zhuhai United Laboratories Latest Developments
Table 116. Biocon Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 117. Biocon Human Recombinant Insulin Product Portfolios and Specifications
Table 118. Biocon Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 119. Biocon Main Business
Table 120. Biocon Latest Developments
Table 121. Wanbang Biopharmaceuticals Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 122. Wanbang Biopharmaceuticals Human Recombinant Insulin Product Portfolios and Specifications
Table 123. Wanbang Biopharmaceuticals Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 124. Wanbang Biopharmaceuticals Main Business
Table 125. Wanbang Biopharmaceuticals Latest Developments
Table 126. Dongbao Enterprise Group Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 127. Dongbao Enterprise Group Human Recombinant Insulin Product Portfolios and Specifications
Table 128. Dongbao Enterprise Group Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 129. Dongbao Enterprise Group Main Business
Table 130. Dongbao Enterprise Group Latest Developments
Table 131. PeproTech Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 132. PeproTech Human Recombinant Insulin Product Portfolios and Specifications
Table 133. PeproTech Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 134. PeproTech Main Business
Table 135. PeproTech Latest Developments
Table 1. Human Recombinant Insulin Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Human Recombinant Insulin Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Rapid-Acting Human Insulin
Table 4. Major Players of Regular (Short Acting) Insulin
Table 5. Major Players of NPH (Intermediate Acting) Insulin
Table 6. Major Players of Long-Acting Human Insulin
Table 7. Major Players of Premixed Human Insulins Insulin
Table 8. Global Human Recombinant Insulin Sales by Type (2018-2023) & (K Litre)
Table 9. Global Human Recombinant Insulin Sales Market Share by Type (2018-2023)
Table 10. Global Human Recombinant Insulin Revenue by Type (2018-2023) & ($ million)
Table 11. Global Human Recombinant Insulin Revenue Market Share by Type (2018-2023)
Table 12. Global Human Recombinant Insulin Sale Price by Type (2018-2023) & (USD/Litre)
Table 13. Global Human Recombinant Insulin Sales by Application (2018-2023) & (K Litre)
Table 14. Global Human Recombinant Insulin Sales Market Share by Application (2018-2023)
Table 15. Global Human Recombinant Insulin Revenue by Application (2018-2023)
Table 16. Global Human Recombinant Insulin Revenue Market Share by Application (2018-2023)
Table 17. Global Human Recombinant Insulin Sale Price by Application (2018-2023) & (USD/Litre)
Table 18. Global Human Recombinant Insulin Sales by Company (2018-2023) & (K Litre)
Table 19. Global Human Recombinant Insulin Sales Market Share by Company (2018-2023)
Table 20. Global Human Recombinant Insulin Revenue by Company (2018-2023) ($ Millions)
Table 21. Global Human Recombinant Insulin Revenue Market Share by Company (2018-2023)
Table 22. Global Human Recombinant Insulin Sale Price by Company (2018-2023) & (USD/Litre)
Table 23. Key Manufacturers Human Recombinant Insulin Producing Area Distribution and Sales Area
Table 24. Players Human Recombinant Insulin Products Offered
Table 25. Human Recombinant Insulin Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Human Recombinant Insulin Sales by Geographic Region (2018-2023) & (K Litre)
Table 29. Global Human Recombinant Insulin Sales Market Share Geographic Region (2018-2023)
Table 30. Global Human Recombinant Insulin Revenue by Geographic Region (2018-2023) & ($ millions)
Table 31. Global Human Recombinant Insulin Revenue Market Share by Geographic Region (2018-2023)
Table 32. Global Human Recombinant Insulin Sales by Country/Region (2018-2023) & (K Litre)
Table 33. Global Human Recombinant Insulin Sales Market Share by Country/Region (2018-2023)
Table 34. Global Human Recombinant Insulin Revenue by Country/Region (2018-2023) & ($ millions)
Table 35. Global Human Recombinant Insulin Revenue Market Share by Country/Region (2018-2023)
Table 36. Americas Human Recombinant Insulin Sales by Country (2018-2023) & (K Litre)
Table 37. Americas Human Recombinant Insulin Sales Market Share by Country (2018-2023)
Table 38. Americas Human Recombinant Insulin Revenue by Country (2018-2023) & ($ Millions)
Table 39. Americas Human Recombinant Insulin Revenue Market Share by Country (2018-2023)
Table 40. Americas Human Recombinant Insulin Sales by Type (2018-2023) & (K Litre)
Table 41. Americas Human Recombinant Insulin Sales by Application (2018-2023) & (K Litre)
Table 42. APAC Human Recombinant Insulin Sales by Region (2018-2023) & (K Litre)
Table 43. APAC Human Recombinant Insulin Sales Market Share by Region (2018-2023)
Table 44. APAC Human Recombinant Insulin Revenue by Region (2018-2023) & ($ Millions)
Table 45. APAC Human Recombinant Insulin Revenue Market Share by Region (2018-2023)
Table 46. APAC Human Recombinant Insulin Sales by Type (2018-2023) & (K Litre)
Table 47. APAC Human Recombinant Insulin Sales by Application (2018-2023) & (K Litre)
Table 48. Europe Human Recombinant Insulin Sales by Country (2018-2023) & (K Litre)
Table 49. Europe Human Recombinant Insulin Sales Market Share by Country (2018-2023)
Table 50. Europe Human Recombinant Insulin Revenue by Country (2018-2023) & ($ Millions)
Table 51. Europe Human Recombinant Insulin Revenue Market Share by Country (2018-2023)
Table 52. Europe Human Recombinant Insulin Sales by Type (2018-2023) & (K Litre)
Table 53. Europe Human Recombinant Insulin Sales by Application (2018-2023) & (K Litre)
Table 54. Middle East & Africa Human Recombinant Insulin Sales by Country (2018-2023) & (K Litre)
Table 55. Middle East & Africa Human Recombinant Insulin Sales Market Share by Country (2018-2023)
Table 56. Middle East & Africa Human Recombinant Insulin Revenue by Country (2018-2023) & ($ Millions)
Table 57. Middle East & Africa Human Recombinant Insulin Revenue Market Share by Country (2018-2023)
Table 58. Middle East & Africa Human Recombinant Insulin Sales by Type (2018-2023) & (K Litre)
Table 59. Middle East & Africa Human Recombinant Insulin Sales by Application (2018-2023) & (K Litre)
Table 60. Key Market Drivers & Growth Opportunities of Human Recombinant Insulin
Table 61. Key Market Challenges & Risks of Human Recombinant Insulin
Table 62. Key Industry Trends of Human Recombinant Insulin
Table 63. Human Recombinant Insulin Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Human Recombinant Insulin Distributors List
Table 66. Human Recombinant Insulin Customer List
Table 67. Global Human Recombinant Insulin Sales Forecast by Region (2024-2029) & (K Litre)
Table 68. Global Human Recombinant Insulin Revenue Forecast by Region (2024-2029) & ($ millions)
Table 69. Americas Human Recombinant Insulin Sales Forecast by Country (2024-2029) & (K Litre)
Table 70. Americas Human Recombinant Insulin Revenue Forecast by Country (2024-2029) & ($ millions)
Table 71. APAC Human Recombinant Insulin Sales Forecast by Region (2024-2029) & (K Litre)
Table 72. APAC Human Recombinant Insulin Revenue Forecast by Region (2024-2029) & ($ millions)
Table 73. Europe Human Recombinant Insulin Sales Forecast by Country (2024-2029) & (K Litre)
Table 74. Europe Human Recombinant Insulin Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Middle East & Africa Human Recombinant Insulin Sales Forecast by Country (2024-2029) & (K Litre)
Table 76. Middle East & Africa Human Recombinant Insulin Revenue Forecast by Country (2024-2029) & ($ millions)
Table 77. Global Human Recombinant Insulin Sales Forecast by Type (2024-2029) & (K Litre)
Table 78. Global Human Recombinant Insulin Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 79. Global Human Recombinant Insulin Sales Forecast by Application (2024-2029) & (K Litre)
Table 80. Global Human Recombinant Insulin Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 81. Novo Nordisk Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 82. Novo Nordisk Human Recombinant Insulin Product Portfolios and Specifications
Table 83. Novo Nordisk Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 84. Novo Nordisk Main Business
Table 85. Novo Nordisk Latest Developments
Table 86. Eli Lilly and Company Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 87. Eli Lilly and Company Human Recombinant Insulin Product Portfolios and Specifications
Table 88. Eli Lilly and Company Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 89. Eli Lilly and Company Main Business
Table 90. Eli Lilly and Company Latest Developments
Table 91. Sanofi Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 92. Sanofi Human Recombinant Insulin Product Portfolios and Specifications
Table 93. Sanofi Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 94. Sanofi Main Business
Table 95. Sanofi Latest Developments
Table 96. Julphar Gulf Pharmaceutical Industries Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 97. Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Product Portfolios and Specifications
Table 98. Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 99. Julphar Gulf Pharmaceutical Industries Main Business
Table 100. Julphar Gulf Pharmaceutical Industries Latest Developments
Table 101. Bioton Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 102. Bioton Human Recombinant Insulin Product Portfolios and Specifications
Table 103. Bioton Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 104. Bioton Main Business
Table 105. Bioton Latest Developments
Table 106. Gan & Lee Pharmaceuticals Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 107. Gan & Lee Pharmaceuticals Human Recombinant Insulin Product Portfolios and Specifications
Table 108. Gan & Lee Pharmaceuticals Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 109. Gan & Lee Pharmaceuticals Main Business
Table 110. Gan & Lee Pharmaceuticals Latest Developments
Table 111. Zhuhai United Laboratories Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 112. Zhuhai United Laboratories Human Recombinant Insulin Product Portfolios and Specifications
Table 113. Zhuhai United Laboratories Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 114. Zhuhai United Laboratories Main Business
Table 115. Zhuhai United Laboratories Latest Developments
Table 116. Biocon Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 117. Biocon Human Recombinant Insulin Product Portfolios and Specifications
Table 118. Biocon Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 119. Biocon Main Business
Table 120. Biocon Latest Developments
Table 121. Wanbang Biopharmaceuticals Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 122. Wanbang Biopharmaceuticals Human Recombinant Insulin Product Portfolios and Specifications
Table 123. Wanbang Biopharmaceuticals Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 124. Wanbang Biopharmaceuticals Main Business
Table 125. Wanbang Biopharmaceuticals Latest Developments
Table 126. Dongbao Enterprise Group Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 127. Dongbao Enterprise Group Human Recombinant Insulin Product Portfolios and Specifications
Table 128. Dongbao Enterprise Group Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 129. Dongbao Enterprise Group Main Business
Table 130. Dongbao Enterprise Group Latest Developments
Table 131. PeproTech Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 132. PeproTech Human Recombinant Insulin Product Portfolios and Specifications
Table 133. PeproTech Human Recombinant Insulin Sales (K Litre), Revenue ($ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 134. PeproTech Main Business
Table 135. PeproTech Latest Developments
LIST OF FIGURES
Figure 1. Picture of Human Recombinant Insulin
Figure 2. Human Recombinant Insulin Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Human Recombinant Insulin Sales Growth Rate 2018-2029 (K Litre)
Figure 7. Global Human Recombinant Insulin Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Human Recombinant Insulin Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Rapid-Acting Human Insulin
Figure 10. Product Picture of Regular (Short Acting) Insulin
Figure 11. Product Picture of NPH (Intermediate Acting) Insulin
Figure 12. Product Picture of Long-Acting Human Insulin
Figure 13. Product Picture of Premixed Human Insulins Insulin
Figure 14. Global Human Recombinant Insulin Sales Market Share by Type in 2022
Figure 15. Global Human Recombinant Insulin Revenue Market Share by Type (2018-2023)
Figure 16. Human Recombinant Insulin Consumed in Hospital
Figure 17. Global Human Recombinant Insulin Market: Hospital (2018-2023) & (K Litre)
Figure 18. Human Recombinant Insulin Consumed in Retail Pharmacy
Figure 19. Global Human Recombinant Insulin Market: Retail Pharmacy (2018-2023) & (K Litre)
Figure 20. Human Recombinant Insulin Consumed in Online Pharmacies
Figure 21. Global Human Recombinant Insulin Market: Online Pharmacies (2018-2023) & (K Litre)
Figure 22. Human Recombinant Insulin Consumed in Other
Figure 23. Global Human Recombinant Insulin Market: Other (2018-2023) & (K Litre)
Figure 24. Global Human Recombinant Insulin Sales Market Share by Application (2022)
Figure 25. Global Human Recombinant Insulin Revenue Market Share by Application in 2022
Figure 26. Human Recombinant Insulin Sales Market by Company in 2022 (K Litre)
Figure 27. Global Human Recombinant Insulin Sales Market Share by Company in 2022
Figure 28. Human Recombinant Insulin Revenue Market by Company in 2022 ($ Million)
Figure 29. Global Human Recombinant Insulin Revenue Market Share by Company in 2022
Figure 30. Global Human Recombinant Insulin Sales Market Share by Geographic Region (2018-2023)
Figure 31. Global Human Recombinant Insulin Revenue Market Share by Geographic Region in 2022
Figure 32. Americas Human Recombinant Insulin Sales 2018-2023 (K Litre)
Figure 33. Americas Human Recombinant Insulin Revenue 2018-2023 ($ Millions)
Figure 34. APAC Human Recombinant Insulin Sales 2018-2023 (K Litre)
Figure 35. APAC Human Recombinant Insulin Revenue 2018-2023 ($ Millions)
Figure 36. Europe Human Recombinant Insulin Sales 2018-2023 (K Litre)
Figure 37. Europe Human Recombinant Insulin Revenue 2018-2023 ($ Millions)
Figure 38. Middle East & Africa Human Recombinant Insulin Sales 2018-2023 (K Litre)
Figure 39. Middle East & Africa Human Recombinant Insulin Revenue 2018-2023 ($ Millions)
Figure 40. Americas Human Recombinant Insulin Sales Market Share by Country in 2022
Figure 41. Americas Human Recombinant Insulin Revenue Market Share by Country in 2022
Figure 42. Americas Human Recombinant Insulin Sales Market Share by Type (2018-2023)
Figure 43. Americas Human Recombinant Insulin Sales Market Share by Application (2018-2023)
Figure 44. United States Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 45. Canada Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 46. Mexico Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 47. Brazil Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 48. APAC Human Recombinant Insulin Sales Market Share by Region in 2022
Figure 49. APAC Human Recombinant Insulin Revenue Market Share by Regions in 2022
Figure 50. APAC Human Recombinant Insulin Sales Market Share by Type (2018-2023)
Figure 51. APAC Human Recombinant Insulin Sales Market Share by Application (2018-2023)
Figure 52. China Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 53. Japan Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 54. South Korea Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 55. Southeast Asia Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 56. India Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 57. Australia Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 58. China Taiwan Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 59. Europe Human Recombinant Insulin Sales Market Share by Country in 2022
Figure 60. Europe Human Recombinant Insulin Revenue Market Share by Country in 2022
Figure 61. Europe Human Recombinant Insulin Sales Market Share by Type (2018-2023)
Figure 62. Europe Human Recombinant Insulin Sales Market Share by Application (2018-2023)
Figure 63. Germany Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 64. France Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 65. UK Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 66. Italy Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 67. Russia Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 68. Middle East & Africa Human Recombinant Insulin Sales Market Share by Country in 2022
Figure 69. Middle East & Africa Human Recombinant Insulin Revenue Market Share by Country in 2022
Figure 70. Middle East & Africa Human Recombinant Insulin Sales Market Share by Type (2018-2023)
Figure 71. Middle East & Africa Human Recombinant Insulin Sales Market Share by Application (2018-2023)
Figure 72. Egypt Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 73. South Africa Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 74. Israel Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 75. Turkey Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 76. GCC Country Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 77. Manufacturing Cost Structure Analysis of Human Recombinant Insulin in 2022
Figure 78. Manufacturing Process Analysis of Human Recombinant Insulin
Figure 79. Industry Chain Structure of Human Recombinant Insulin
Figure 80. Channels of Distribution
Figure 81. Global Human Recombinant Insulin Sales Market Forecast by Region (2024-2029)
Figure 82. Global Human Recombinant Insulin Revenue Market Share Forecast by Region (2024-2029)
Figure 83. Global Human Recombinant Insulin Sales Market Share Forecast by Type (2024-2029)
Figure 84. Global Human Recombinant Insulin Revenue Market Share Forecast by Type (2024-2029)
Figure 85. Global Human Recombinant Insulin Sales Market Share Forecast by Application (2024-2029)
Figure 86. Global Human Recombinant Insulin Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Human Recombinant Insulin
Figure 2. Human Recombinant Insulin Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Human Recombinant Insulin Sales Growth Rate 2018-2029 (K Litre)
Figure 7. Global Human Recombinant Insulin Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Human Recombinant Insulin Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Rapid-Acting Human Insulin
Figure 10. Product Picture of Regular (Short Acting) Insulin
Figure 11. Product Picture of NPH (Intermediate Acting) Insulin
Figure 12. Product Picture of Long-Acting Human Insulin
Figure 13. Product Picture of Premixed Human Insulins Insulin
Figure 14. Global Human Recombinant Insulin Sales Market Share by Type in 2022
Figure 15. Global Human Recombinant Insulin Revenue Market Share by Type (2018-2023)
Figure 16. Human Recombinant Insulin Consumed in Hospital
Figure 17. Global Human Recombinant Insulin Market: Hospital (2018-2023) & (K Litre)
Figure 18. Human Recombinant Insulin Consumed in Retail Pharmacy
Figure 19. Global Human Recombinant Insulin Market: Retail Pharmacy (2018-2023) & (K Litre)
Figure 20. Human Recombinant Insulin Consumed in Online Pharmacies
Figure 21. Global Human Recombinant Insulin Market: Online Pharmacies (2018-2023) & (K Litre)
Figure 22. Human Recombinant Insulin Consumed in Other
Figure 23. Global Human Recombinant Insulin Market: Other (2018-2023) & (K Litre)
Figure 24. Global Human Recombinant Insulin Sales Market Share by Application (2022)
Figure 25. Global Human Recombinant Insulin Revenue Market Share by Application in 2022
Figure 26. Human Recombinant Insulin Sales Market by Company in 2022 (K Litre)
Figure 27. Global Human Recombinant Insulin Sales Market Share by Company in 2022
Figure 28. Human Recombinant Insulin Revenue Market by Company in 2022 ($ Million)
Figure 29. Global Human Recombinant Insulin Revenue Market Share by Company in 2022
Figure 30. Global Human Recombinant Insulin Sales Market Share by Geographic Region (2018-2023)
Figure 31. Global Human Recombinant Insulin Revenue Market Share by Geographic Region in 2022
Figure 32. Americas Human Recombinant Insulin Sales 2018-2023 (K Litre)
Figure 33. Americas Human Recombinant Insulin Revenue 2018-2023 ($ Millions)
Figure 34. APAC Human Recombinant Insulin Sales 2018-2023 (K Litre)
Figure 35. APAC Human Recombinant Insulin Revenue 2018-2023 ($ Millions)
Figure 36. Europe Human Recombinant Insulin Sales 2018-2023 (K Litre)
Figure 37. Europe Human Recombinant Insulin Revenue 2018-2023 ($ Millions)
Figure 38. Middle East & Africa Human Recombinant Insulin Sales 2018-2023 (K Litre)
Figure 39. Middle East & Africa Human Recombinant Insulin Revenue 2018-2023 ($ Millions)
Figure 40. Americas Human Recombinant Insulin Sales Market Share by Country in 2022
Figure 41. Americas Human Recombinant Insulin Revenue Market Share by Country in 2022
Figure 42. Americas Human Recombinant Insulin Sales Market Share by Type (2018-2023)
Figure 43. Americas Human Recombinant Insulin Sales Market Share by Application (2018-2023)
Figure 44. United States Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 45. Canada Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 46. Mexico Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 47. Brazil Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 48. APAC Human Recombinant Insulin Sales Market Share by Region in 2022
Figure 49. APAC Human Recombinant Insulin Revenue Market Share by Regions in 2022
Figure 50. APAC Human Recombinant Insulin Sales Market Share by Type (2018-2023)
Figure 51. APAC Human Recombinant Insulin Sales Market Share by Application (2018-2023)
Figure 52. China Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 53. Japan Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 54. South Korea Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 55. Southeast Asia Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 56. India Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 57. Australia Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 58. China Taiwan Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 59. Europe Human Recombinant Insulin Sales Market Share by Country in 2022
Figure 60. Europe Human Recombinant Insulin Revenue Market Share by Country in 2022
Figure 61. Europe Human Recombinant Insulin Sales Market Share by Type (2018-2023)
Figure 62. Europe Human Recombinant Insulin Sales Market Share by Application (2018-2023)
Figure 63. Germany Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 64. France Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 65. UK Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 66. Italy Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 67. Russia Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 68. Middle East & Africa Human Recombinant Insulin Sales Market Share by Country in 2022
Figure 69. Middle East & Africa Human Recombinant Insulin Revenue Market Share by Country in 2022
Figure 70. Middle East & Africa Human Recombinant Insulin Sales Market Share by Type (2018-2023)
Figure 71. Middle East & Africa Human Recombinant Insulin Sales Market Share by Application (2018-2023)
Figure 72. Egypt Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 73. South Africa Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 74. Israel Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 75. Turkey Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 76. GCC Country Human Recombinant Insulin Revenue Growth 2018-2023 ($ Millions)
Figure 77. Manufacturing Cost Structure Analysis of Human Recombinant Insulin in 2022
Figure 78. Manufacturing Process Analysis of Human Recombinant Insulin
Figure 79. Industry Chain Structure of Human Recombinant Insulin
Figure 80. Channels of Distribution
Figure 81. Global Human Recombinant Insulin Sales Market Forecast by Region (2024-2029)
Figure 82. Global Human Recombinant Insulin Revenue Market Share Forecast by Region (2024-2029)
Figure 83. Global Human Recombinant Insulin Sales Market Share Forecast by Type (2024-2029)
Figure 84. Global Human Recombinant Insulin Revenue Market Share Forecast by Type (2024-2029)
Figure 85. Global Human Recombinant Insulin Sales Market Share Forecast by Application (2024-2029)
Figure 86. Global Human Recombinant Insulin Revenue Market Share Forecast by Application (2024-2029)
